Objectives We aimed to study the association of fibroblast growth factor-23 (FGF-23) with conventional cardiovascular risk factors in hemodialysis (HD) patients. Patients and methods This is a cross-sectional study, which was carried out on 90 HD patients. Demographic data were recorded in predefined data sheets. The blood samples for FGF-23 and other laboratory variables were collected and measured using the standard methods. The results and their relationships with FGF-23 were analyzed. Results In our study, there were insignificant correlations between FGF-23 and all clinical cardiovascular variables apart from a significant positive correlation between FGF- 23 and systolic blood pressure (r=−0.546, P=0.004). Multivariate analysis failed to show any significant association between FGF-23 and systolic blood pressure (B=0.749, T=1.659, P=0.067). Conclusion Multiple linear regression analysis failed to show any significant association between FGF-23 and other conventional cardiovascular risk factors. We recommend using FGF-23 as an independent risk factor of cardiovascular morbidity and mortality, and searching for agents that control its level in HD patients.

Objectives We aimed to study the association of fibroblast growth factor-23 (FGF-23) with conventional cardiovascular risk factors in hemodialysis (HD) patients. Patients and methods This is a cross-sectional study, which was carried out on 90 HD patients. Demographic data were recorded in predefined data sheets. The blood samples for FGF-23 and other laboratory variables were collected and measured using the standard methods. The results and their relationships with FGF-23 were analyzed. Results In our study, there were insignificant correlations between FGF-23 and all clinical cardiovascular variables apart from a significant positive correlation between FGF- 23 and systolic blood pressure (r=−0.546, P=0.004). Multivariate analysis failed to show any significant association between FGF-23 and systolic blood pressure (B=0.749, T=1.659, P=0.067). Conclusion Multiple linear regression analysis failed to show any significant association between FGF-23 and other conventional cardiovascular risk factors. We recommend using FGF-23 as an independent risk factor of cardiovascular morbidity and mortality, and searching for agents that control its level in HD patients.

Objectives We aimed to study the association of fibroblast growth factor-23 (FGF-23) with conventional cardiovascular risk factors in hemodialysis (HD) patients. Patients and methods This is a cross-sectional study, which was carried out on 90 HD patients. Demographic data were recorded in predefined data sheets. The blood samples for FGF-23 and other laboratory variables were collected and measured using the standard methods. The results and their relationships with FGF-23 were analyzed. Results In our study, there were insignificant correlations between FGF-23 and all clinical cardiovascular variables apart from a significant positive correlation between FGF- 23 and systolic blood pressure (r=−0.546, P=0.004). Multivariate analysis failed to show any significant association between FGF-23 and systolic blood pressure (B=0.749, T=1.659, P=0.067). Conclusion Multiple linear regression analysis failed to show any significant association between FGF-23 and other conventional cardiovascular risk factors. We recommend using FGF-23 as an independent risk factor of cardiovascular morbidity and mortality, and searching for agents that control its level in HD patients.

We aimed to study the association of fibroblast growth factor-23 (FGF-23) as a novel cardiovascular risk factor with Doppler pulse wave velocity (PWV) as an arterial stiffness measuring tool in hemodialysis (HD) patients. We conducted a cross-sectional study in which blood samples from 86 HD patients were obtained to estimate FGF 23 and other parameters. Flow waveforms were obtained at two locations within right common carotid artery, and right femoral artery by Doppler ultrasound with ECG recorded in addition. The time differences between the R wave of the ECG signal and the onset of the flow waveforms at the two sites yield ΔT. Distances between sampling sites were measured using a tape measure. PWV was defined as (m/s) = D (m)/ΔT (s). In the current study, we found significant positive correlations between Doppler PWV and both age (r = 0.401, P = 0.039) and systolic blood pressure (r = 0.602, P = 0.034), while no significant association between Doppler PWV and FGF-23 (r = 0.123, P = 0.259) could be detected. Serum FGF-23 levels are not significantly associated with Doppler PWV in HD patients.

We aimed to study the association of fibroblast growth factor-23 (FGF-23) as a novel cardiovascular risk factor with Doppler pulse wave velocity (PWV) as an arterial stiffness measuring tool in hemodialysis (HD) patients. We conducted a cross-sectional study in which blood samples from 86 HD patients were obtained to estimate FGF 23 and other parameters. Flow waveforms were obtained at two locations within right common carotid artery, and right femoral artery by Doppler ultrasound with ECG recorded in addition. The time differences between the R wave of the ECG signal and the onset of the flow waveforms at the two sites yield ΔT. Distances between sampling sites were measured using a tape measure. PWV was defined as (m/s) = D (m)/ΔT (s). In the current study, we found significant positive correlations between Doppler PWV and both age (r = 0.401, P = 0.039) and systolic blood pressure (r = 0.602, P = 0.034), while no significant association between Doppler PWV and FGF-23 (r = 0.123, P = 0.259) could be detected. Serum FGF-23 levels are not significantly associated with Doppler PWV in HD patients.

We aimed to study the association of fibroblast growth factor-23 (FGF-23) as a novel cardiovascular risk factor with Doppler pulse wave velocity (PWV) as an arterial stiffness measuring tool in hemodialysis (HD) patients. We conducted a cross-sectional study in which blood samples from 86 HD patients were obtained to estimate FGF 23 and other parameters. Flow waveforms were obtained at two locations within right common carotid artery, and right femoral artery by Doppler ultrasound with ECG recorded in addition. The time differences between the R wave of the ECG signal and the onset of the flow waveforms at the two sites yield ΔT. Distances between sampling sites were measured using a tape measure. PWV was defined as (m/s) = D (m)/ΔT (s). In the current study, we found significant positive correlations between Doppler PWV and both age (r = 0.401, P = 0.039) and systolic blood pressure (r = 0.602, P = 0.034), while no significant association between Doppler PWV and FGF-23 (r = 0.123, P = 0.259) could be detected. Serum FGF-23 levels are not significantly associated with Doppler PWV in HD patients.

TAS-102 (trifluorothymidine [TFT] and thymidine phosphorylase inhibitor [TPI] in a molar ratio of 1:0.5) has activity in 5-fluorouracil resistant colon cancer. TPI is added to increase TFT's bioavailability. TFT has a dual mechanism of action by inhibiting thymidylate synthase and by its incorporation into DNA. Interesting radiosensitizing effects of TPI were recently reported. The aim of our study was to determine whether TP expression would affect radiosensitivity and to characterize the effect of TPI. Two bladder cancer cell lines RT112 (TP negative) and RT112/TP (TP overexpression) were tested for drug sensitivity and radiosensitivity (clonogenic assay), with and without TFT and/or TPI. Expression of γ H2AX was used as marker for DNA damage. RT112 cells were not more sensitive to TFT then RT112/TP cells. TPI alone did not inhibit cell growth of RT112 even at 100 μM, but inhibited that of RT112/TP by 27%. In both RT112 and RT112/TP cells 10 μM TPI did not or slightly affect radiosensitivity, but 100 μM TPI alone enhanced the radiation response (p .05). TFT alone at 1 μM and in combination with 10 μM TPI did not affect the radiation response of both cell lines. TPI alone induced expression of ϒH2AX, which was increased in combination with radiation. In conclusion, TPI enhanced radiosensitivity at high concentrations, independent of TP expression, while TFT and TPI at a low concentration did not affect the radiosensitivity of RT112 and RT112/TP cell lines

TAS-102 (trifluorothymidine [TFT] and thymidine phosphorylase inhibitor [TPI] in a molar ratio of 1:0.5) has activity in 5-fluorouracil resistant colon cancer. TPI is added to increase TFT's bioavailability. TFT has a dual mechanism of action by inhibiting thymidylate synthase and by its incorporation into DNA. Interesting radiosensitizing effects of TPI were recently reported. The aim of our study was to determine whether TP expression would affect radiosensitivity and to characterize the effect of TPI. Two bladder cancer cell lines RT112 (TP negative) and RT112/TP (TP overexpression) were tested for drug sensitivity and radiosensitivity (clonogenic assay), with and without TFT and/or TPI. Expression of γ H2AX was used as marker for DNA damage. RT112 cells were not more sensitive to TFT then RT112/TP cells. TPI alone did not inhibit cell growth of RT112 even at 100 μM, but inhibited that of RT112/TP by 27%. In both RT112 and RT112/TP cells 10 μM TPI did not or slightly affect radiosensitivity, but 100 μM TPI alone enhanced the radiation response (p .05). TFT alone at 1 μM and in combination with 10 μM TPI did not affect the radiation response of both cell lines. TPI alone induced expression of ϒH2AX, which was increased in combination with radiation. In conclusion, TPI enhanced radiosensitivity at high concentrations, independent of TP expression, while TFT and TPI at a low concentration did not affect the radiosensitivity of RT112 and RT112/TP cell lines

NULL

NULL